Bonus share: Today, in this post we’ll discuss about Shukra Pharmaceuticals latest news, fundamentals, potential growth areas, and all sorts of information regarding this company to gain a better understanding. We hope our analysis will provide you better insight about the company.
Shares of Shukra Pharmaceuticals, a small-cap company in the pharmaceutical industry, are in focus these days.
Shares of the company rose by 1.99% on Wednesday and reached at Rs 319.65.
Shareholders of Shukra Pharmaceuticals will get 3 shares of the company for every 1 share as a bonus.
For this, the company has announced a record date. The company has fixed April 20, 2024, as the record date for giving bonus shares in the ratio of 3:1.
Condition Of Shares
Shukra Pharmaceuticals is a renowned public limited company with production sites across the world.
Shares of the pharmaceutical company hit an upper circuit of 2% on Monday after the company’s board member announced a record date for 3:1 bonus shares.
Shares of Shukra Pharmaceuticals hit a 52-week high of Rs 388.00 on (07/03/2024) and a 52-week low of Rs 50.34 on (10/04/2023).
Brokerage Opinion
Expert said that this has been a high-growth stock for many investors and is now trading at 319. If gets a breakdown of the 290 range and closes below If this happens then a little more correction is expected on the charts and valuation and this may be considered as a value dip buying opportunity.
This is a high-swing stock, so it would be good to buy in the 215 to 240 range. Target 350 to 350. Keep it between Rs 510 and stop loss at Rs 200.
About Shukra Pharmaceuticals
Shukra Pharmaceuticals Limited is an India-based firm, principally involved in manufacturing and marketing pharmaceutical products.
The company operates in two areas which include laboratory and pharmaceutical.
The company’s product portfolio comprises antibiotics (penicillin) and anti-biotics (cephalosporin) anti-biotics, macrolides, quinolones, and anti-fungal medications,
as well as anti-malarial and anti-protozoal, antiviral, anti-anthelmintic tranquilizer and sedative, anti-depressant as well as anti-manic and anti-emetic beta blockers diuretics, analgesics and analgesic (NASID) and muscle relaxants, antituberculosis products, anti-allergic corticosteroids, hypo and hyperglycemic.
The company is involved in the manufacture of general formulations including capsules, tablets, and small-volume parenteral.
Fundamental Analysis of Shukra Pharmaceuticals
| Market Cap | ₹ 350 Cr. |
| Current Price | ₹ 319.65 |
| 52-wk High | ₹ 388 |
| 52-wk Low | ₹54.6 |
| Stock P/E | 18.9 |
| Book Value | ₹ 40.8 |
| Dividend | 0.04 % |
| ROCE | 18.8 % |
| ROE | 21.2 % |
| Face Value | ₹ 10.0 |
| P/B Value | 7.83 |
| OPM | 17.0 % |
| EPS | ₹ 17.1 |
| Debt | ₹ 2.31 Cr. |
| Debt to Equity | 0.05 |
Shukra Pharmaceuticals Shareholding Pattern
| Promoters Holding | |
| Dec 2022 | 49.16% |
| Mar 2023 | 50.90% |
| June 2023 | 50.90% |
| Sept 2023 | 50.90% |
| Dec 2023 | 50.95% |
| DII Holding | |
| Dec 2022 | 0.80% |
| Mar 2023 | 0.11% |
| June 2023 | 0.11% |
| Sept 2023 | 0.11% |
| Dec 2023 | 0.11% |
| Public Holding | |
| Dec 2022 | 50.04% |
| Mar 2023 | 48.99% |
| June 2023 | 48.99% |
| Sept 2023 | 48.99% |
| Dec 2023 | 48.93% |
Shukra Pharmaceuticals Share: Last 5 Years’ Financial Condition
To gain a better understanding of how the market is performing, let’s look at the outlook of this share in the previous years.
However, investors should be aware of the risks and the market conditions before making any investment decision.
Last 5 Years’ Sales:
| 2019 | ₹6 Cr |
| 2020 | ₹12 Cr |
| 2021 | ₹11 Cr |
| 2022 | ₹20 Cr |
| 2023 | ₹110 Cr |
Last 5 Years’ Net Profit:
| 2019 | ₹0 Cr |
| 2020 | ₹0 Cr |
| 2021 | ₹0 Cr |
| 2022 | ₹1 Cr |
| 2023 | ₹19 Cr |
Last 5 Years’ Debt-To-Equity Ratio:
| 2019 | 0.39 |
| 2020 | 0.52 |
| 2021 | 0.63 |
| 2022 | 0.21 |
| 2023 | 0.2 |
Last 10 Years’ Profit Growth:
| 10 Years: | 36% |
| 5 Years: | 53% |
| 3 Years: | 504% |
| Current Year: | 1600% |
Last 10 years’ Return on Equity (ROE):
| 10 Years: | 4% |
| 5 Years: | 7% |
| 3 Years: | 10% |
| Last Year: | 21% |
Sales Growth Over 10 Years:
| 10 Years: | 28% |
| 5 Years: | 62% |
| 3 Years: | 71% |
| Current Year: | 411% |
Conclusion
This article is a complete guide about Shukra Pharmaceuticals Share.
These information and forecasts are based on our analysis, research, company fundamentals and history, experiences, and various technical analyses.
Also, We have talked in detail about the share’s future prospects and growth potential.
Hopefully, these informations will help you in your further investment.
If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.
If you have any further queries, please comment below. We will be happy to answer all your questions.
If you like this information, share the article with as many people as possible.
Disclaimer: The information on this site is only for informational and educational purposes and shouldn’t be considered financial advice or stock recommendations. We are here to provide timely updates about the stock market and financial products to help you make better investment choices.
